pharmaphorum Podcast

In a new episode of the pharmaphorum podcast, Nicole Raleigh invites Mati Gill, CEO of AION Labs, back as guest.

AION Labs is a venture studio built by a coalition of pharma heavyweights, tech giants, and leading investors to develop and integrate AI technologies to redefine drug discovery and development through the creation of new start-ups.

Gill discusses some great start-ups coming out of the AION Labs co-development model, what investors now expect of AI biotech companies, and the potential of AI in drug discovery and development for the good of human health.

You can listen to episode 284 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it – and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.

At ESMO 2026, Taiho Oncology presented data from Cohort C of the Phase 2 REZILIENT2 trial evaluating zipalertinib monotherapy in patients with locally advanced or metastatic non-small cell lung cancer (or NSCLC) harbouring epidermal growth factor receptor (or EGFR) exon 20 insertion mutations or other uncommon EGFR mutations and active central nervous system (or CNS) metastases.

During the Congress, pharmaphorum’s Nicole Raleigh invited Dr Harold Keer, chief medical officer at Taiho Oncology, as a guest on the podcast while he was on the ground in Madrid, Spain.

Dr Keer discusses the non-small cell lung cancer patient and treatment setting, as well as improving the lives of patients with cancer, their families, and their caregivers. He also goes into detail on Taiho’s orally administered anti-cancer agents for various tumour types and an expanding pipeline of antibody-drug conjugate (or ADC) therapies.

Listen to the conversation and explore our updates from ESMO 2026 here.

As the European Society for Medical Oncology 2026 Congress commences in Madrid, pharmaphorum invited Syncromune Executive Chairman Dr Chuck Link onto the podcast for a conversation on the updated long-term overall survival data from its Phase 1 trial of SYNC-T Therapy SV-102 in patients with metastatic prostate cancer.

Dr Link discusses SYNC-T, their investigational in situ personalised immunotherapy, as well as metastatic castration-resistant (or mCRPC) and metastatic hormone-sensitive (or mHSPC) disease, and the possible outcomes for patients going forward.

Listen to the conversation and keep up on ESMO26 updates here.

*This episode of the pharmaphorum podcast is brought to you in association with Klick Health*

By 2030, 1.2 billion women worldwide will be menopausal or post-menopausal - many at the peak of their working lives. Yet, menopause remains largely absent from health system planning, despite growing evidence linking unmanaged symptoms to reduced productivity, absenteeism, and women leaving the workforce altogether.

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Dr Cecilia Caetano, vice president, global medical affairs and evidence generation lead in women’s health at Bayer, for a conversation on this overlooked, but increasingly urgent global health issue.

Caetano discusses the lack of innovation in women’s health and, critically, the lack of understanding of menopausal needs. She also explores the European landscape for menopause in comparison to the UK, as well as describing what ‘health system readiness’ looks like.

You can listen to episode 281 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it – and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.

*This episode of the pharmaphorum podcast is brought to you in association with Klick Health*

Even the most promising innovation still depends on strong governance, resilient operations, and confidence in sensitive data.

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Robbie Tyrie, founder and managing director of Torridon Cyber, for a conversation on cybersecurity when it comes to pharma companies and health systems more widely.

Tyrie shares his insights and explains how to ensure cybersecurity acts as a business enabler, as opposed to a barrier to growth.

You can listen to episode 280 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it – and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.

Industry is using AI to surface hidden patterns and accelerate decision-making in high-pressure launch environments.

In a new pharmaphorum podcast, host Nicole Raleigh speaks with Jason Smith, CTO of AI and analytics at Within3, for a conversation on data-fuelled agile launches and smarter decision-making.

Smith discusses alignment of cross-functional teams and fostering real collaboration and efficiency, how pharma teams can use real-time data to shape more precise and effective launch strategies, and the importance in all this of maintaining a deep focus on patient needs and healthcare provider challenges.

You can listen to episode 279 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it – and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.

Bioconvergence is a multidisciplinary research and development approach that merges technologies from biology, engineering, and computation, providing solutions in medicine, food, agriculture, manufacturing, climate, and more.

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Shai Melcer, head of the national bioconvergence programme at Israel Innovation Authority, for a conversation exploring bioconvergence broadly.

Melcer discusses the foundations, goes into detail about companies currently working in the bioconvergence space, and what it could – all together – mean for the future of human health.

You can listen to episode 278 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it – and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.

Artificial intelligence is dramatically transforming the landscape for every part of pharma. One area where AI is both essential to implement and important to get right is pharmacovigilance, the group concerned with monitoring and maintaining patient safety.

In today's pharmaphorum podcast, sponsored by IQVIA Safety Solutions, host Jonah Comstock speaks with Updesh Dosanjh, IQVIA commercialisation lead for safety technology, about how and why the role of AI in pharmacovigilance is changing, as well as tips for implementing these new tools safely and reliably.

Dosanjh discusses why AI in pharmacovigilance is moving beyond document extraction and case processing, how regulatory expectations are shifting from basic compliance to meaningful patient outcomes, and why governance and monitoring matter more than technology alone.

Then, in the second half of the conversation, he covers how organisations can build trust and adoption across their teams, what patient-level safety monitoring could look like in the era of personalised medicine, and, finally, why starting with a meaningful, high-value use case is critical to AI success.

Check out the full podcast below, and then download the White Paper to learn even more.

Earlier this year, the FDA released draft guidance endorsing Bayesian methods and simulation-based evidence in clinical trials in a significant shift in how regulators think about predictive medicine.

In a new pharmaphorum podcast, Dr Irina Babina, CEO of oncology R&D platform Concr, discusses how current regulatory frameworks were built for static, one-test-one-answer diagnostics, as well as the potential of digital twins, and how, if regulators keep approving AI medical tools the way they approve blood tests, the most promising predictive technologies will never reach patients.

You can listen to episode 276 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it – and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.

*This episode of the pharmaphorum podcast is brought to you in association with Klick Health*

Europe continues to offer major life sciences advantages: deep scientific talent, strong clinical expertise, mature research infrastructure, and significant manufacturing capability. Indeed, biotech companies continue to invest in Europe as a long-term hub for scientific innovation, clinical research, and economic growth.

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Giancarlo Benelli, SVP & Head of Europe at BeOne Medicines, for a conversation on what Europe must do, however, in order to remain globally competitive.

Benelli discusses EFPIA’s latest reports on Europe’s competitiveness as a location for the life sciences industry, as well as exploring why it is at the same time losing ground to the US and to China. Additionally, Benelli comments on the importance of regulatory stability looking forward.

You can listen to episode 275 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it – and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.

*This episode of the pharmaphorum podcast is brought to you in association with Klick Health*

*This episode of the pharmaphorum podcast is brought to you in association with Klick Health*

When it comes to digital innovation and AI, consideration of using and implementing such responsibly and ethically ever more becomes forefront. But how can pharma lead the way in ethical AI and trust-driven innovation?

In a new pharmaphorum podcast, Erik Janssen, head of digital care transformation at UCB, joins web editor Nicole Raleigh for a conversation on responsible digital innovation and ethical AI.

Janssen discusses how pharma can lead in responsible experimentation by focusing digital innovation on enhancing (not replacing) human care. He also speaks about co‑creating solutions with clinicians and patients, as well as the role of evidence‑based technology across the innovation framework.

You can listen to episode 274 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it – and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.

*This episode of the pharmaphorum podcast is brought to you in association with Klick Health*

Public demand for prevention is surging, with 33.6 million people now using the NHS App, yet, NHS leaders say the digital infrastructure required to deliver prevention at scale isn’t in place.

In a new episode of the podcast, pharmaphorum spoke with James Davis, a healthcare expert at PA Consulting, for a conversation on the digital foundations needed to unlock a prevention first NHS.

Davis also discusses the initiatives with the biggest near term impact, what NHS leaders are worried about, and issues of trust and inequality.

You can listen to episode 273 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it – and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.

For a variety of reasons, early stage clinical trials have been moving out of the United States more and more over the past few years, as companies pursue savings and lighter regulatory burden in places like China and Australia. The industry has long urged the US government to take some action to make it more attractive to bring these trials back to the States. That's the broad idea behind Operation TRIALBLAZER, a campaign launched this summer by HHS and the FDA.

On today's podcast, host Jonah Comstock is joined by Dr Harpreet Singh, currently chief medical officer at Precision for Medicine. That's her first private sector job after nearly nine years at the FDA, so she's able to bring both an insider and outsider perspective in discussing this initiative.

In addition to sharing some details about her time at the FDA and how the organisation has changed, Dr Singh discusses the situation in clinical research that's led to the US' leadership in clinical trials slipping away, what's in the Trialblazer plans, and whether she thinks it will be enough to turn the tide.

They also talk a little bit about radiotherapeutics regulation and discuss why having clinical trials in the United States is important not just for the economy, but also for patients who are missing out on opportunities for cutting-edge care.

Tune in for a fascinating primer on a major new US government clinical trials initiative.

Chronic liver disease affects around 1.5 billion people globally. As understanding of liver disease improves, outcomes are increasingly determined by how early patients are identified, not just what therapies are available.

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Lee Lehman Becker, Roche’s global head of healthcare insights at Roche Information Solutions (RIS), for a discussion of the liver disease epidemic that is being diagnosed too late and driving a growing health system crisis globally.

The conversation also explores scalable diagnostic innovation and the role of this in addressing health system burden – metabolic liver disease projected to affect some 1.8 billion people by 2050, with global costs expected to exceed $2.3 trillion.

You can listen to episode 271 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it – and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.

The drug price negotiation provisions in the Inflation Reduction Act were designed to continue evolving with each passing year. As CMS prepares for 2028 and 2029, the agency has put out new draft guidance codifying and, in some cases, modifying the fine print of the controversial law. They’ve also recently issued additional draft guidance on how they’ll handle the imminent introduction of Part B drugs into the programme.

Hogan Lovells partner Alice Valder Curran returned to join pharmaphorum editor-in-chief Jonah Comstock to elucidate some of the finer points of this latest communication from CMS – and to urge the industry to take advantage of the public comment periods associated with it.

Curran and Comstock discuss small, but impactful, changes in CMS’s policies around deemed biologics, vaccines, and the special provisions that protect small biotechs. And Curran gives a rundown of what’s in – as well as what’s not in – the new MFP effectuation guidance, laying out how the differences in how Part D and Part B drugs are paid for leave some big question marks hanging over the programme.

Tune in for an easy-to-understand deep dive into some complicated subject matter, and for a more comprehensive rundown don’t forget to check out Hogan Lovells’ policy briefs on the new draft rules and the MFP effectuation guidance.

SYNGAP1-related disorder negatively impacts synaptic signalling during critical periods of brain development, leading to a range of cognitive, epileptic, behavioural, and motor symptoms.

In a new episode of the pharmaphorum podcast, web editor Nicole Raleigh spoke with Kelly Gold, CFO of CAMP4 Therapeutics, about antisense oligonucleotides (or ASOs) - medicines designed to selectively restore natural protein production in diseases caused by gene under expression.

Gold discusses the space and CAMP4’s CMP-002 study, targeting the regRNA associated SYNGAP1 gene. You can listen to episode 269 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it – and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.

The M&A market has been rebounding in the US, driven by factors like patent cliffs and improved balance sheets – but the question is whether this will play out in Europe and how the wave could differ.

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Andrea Carta Mantiglia, partner and lead of the Healthcare & Life Sciences Focus Team at Italian law firm BonelliErede, about whether the current US biotech M&A surge will indeed extend into Europe.

The conversation touches upon the appetite for cross-border dealmaking, the growing role of private equity in European pharma and medtech, generational exits among family-owned pharma groups in Italy, and the role of digitalisation in all this.

You can listen to episode 268 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it – and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.

Purespring Therapeutics is a precision nephrology company pioneering first-in-class, targeted genetic therapies designed to preserve kidney function.

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Haseeb Ahmad, CEO of Purespring, who discusses transforming the treatment of kidney disease, an area of enormous unmet need, with more than 840 million people worldwide living with chronic kidney disease.

Indeed, Purespring’s lead programme is the podocyte-targeted gene therapy PS-002, which is for IgA nephropathy (or IgAN). The conversation also touches upon the evolution of the gene therapy landscape more generally, and where next with this type of innovation in the nephrology space.

You can listen to episode 267 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it – and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.

Europe's biotech sector is facing an innovation cliff, with fewer clinical starts, tighter capital, and increasing development complexity.

In a new pharmaphorum podcast, web editor Nicole Raleigh caught up with Paul Bridges, president, consulting, at Parexel, and Charlotte Moser, Parexel’s chief medical officer, following BIO-Europe Spring in Lisbon, Portugal.

The conversation touches upon regulatory strategy and evolving policy shifts, trial design and execution – and the importance of patient centricity – as well as AI in drug development and medical leadership in drug development today.

You can listen to episode 266 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it – and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.

Cutaneous T-cell lymphoma (or CTCL) is a rare form of non-Hodgkin lymphoma that begins in T lymphocytes, a kind of white blood cell that plays a crucial role in the immune system. And Citius Oncology is focused on developing and commercialising a targeted immune therapy for the initial indication of the treatment of persistent or recurrent CTCL.

In a new pharmaphorum podcast, web editor Nicole Raleigh spoke with Leonard Mazur, CEO and Chairman of Citius Pharmaceuticals about the launch of its first FDA-approved drug, Lymphir, for CTCL.

Mazur discusses the landscape of unmet need in this space, as well as Citius’ advancement of clinical trials in other areas without approved treatments and the future horizon for such oncological innovations.

You can listen to episode 265 of the pharmaphorum podcast in the player below, download the episode to your computer, or find it – and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.